Adaptimmune Announces Commercial Development and Supply Agreement for Thermo Fisher Scientific's Dynabeads(TM) CD3/CD28 Cell Therapy System
(Thomson Reuters ONE) -
PHILADELPHIA and OXFORD, United Kingdom, June 21, 2016 (GLOBE NEWSWIRE) --
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat
cancer, today announced that it has entered into a commercial development and
supply agreement with Thermo Fisher Scientific. The new 10-year agreement
augments Adaptimmune's exclusive license and supply relationship with Thermo
Fisher for the Dynabeads CD3/CD28 Cell Therapy System (CTS(TM))* for use in the
manufacture of Adaptimmune's SPEAR(TM) T-cell therapies.
Dynabeads(TM) CD3/CD28 CTS is designed to isolate, activate and expand human T-
cells. This technology provides coordinated and simultaneous activation and co-
stimulation signals to T-cells, a process that is reported to produce T-cells
with enhanced proliferation and with characteristics that enable prolonged
persistence in vivo**. Adaptimmune has an exclusive license for the IP
associated with the use of Dynabeads CD3/CD28 to expand and activate all TCR-
transduced T-cells in cancer, infectious and autoimmune diseases.
"We are delighted to expand our collaboration with Thermo Fisher and secure
continuity of supply of Dynabeads through commercialization," said Gwen Binder-
Scholl, Adaptimmune's Chief Technology Officer. "Dynabeads CD3/CD28 have unique
properties which we believe optimize the manufacture of our SPEAR T-cell
therapies, including the generation of younger and healthier T-cells leading to
prolonged persistence of therapeutic cells in the blood. We look forward to
continuing to work closely with Thermo Fisher as we progress toward the
commercialization of our T-cell therapeutics."
"Thermo Fisher's market-leading cell therapy workflow solutions are enabling its
customers to address the unique commercialization challenges of this market. We
are pleased to expand our partnership with Adaptimmune, a leader in the T-cell
immunotherapy space," said Oystein Aamellem, director of Cellular Medicine for
Thermo Fisher. "This agreement demonstrates our sustained commitment to
advancing the development of our Dynabead CD3/CD28 technology to support the
treatment of solid tumors, as well as other conditions that threaten human
health."
Adaptimmune's SPEAR T-cell therapies are novel cancer immunotherapies that have
been engineered through their T cell receptors (TCRs) to target and destroy
cancer cells by strengthening a patient's natural T-cell response. T-cells are a
type of white blood cell that play a central role in a person's immune response.
Adaptimmune's goal is to harness the power of the T-cell and, through its
multiple therapeutic candidates, significantly impact cancer treatment and
clinical outcomes of patients with solid and hematologic cancers.
The manufacturing process consists of isolating T-cells from the blood of cancer
patients; transferring affinity enhanced TCRs, which have been modified to
recognize cancer cells, into the cells; activating and expanding the T-cells
using Dynabeads CD3/CD28; and, introducing the affinity enhanced cells back into
the patient to enable the patient's immune system to respond and attack cancer.
About Adaptimmune
Adaptimmune is a clinical stage biopharmaceutical company focused on novel
cancer immunotherapy products based on its SPEAR (Specific Peptide Enhanced
Affinity Receptor) T-cell platform. Established in 2008, the company aims to
utilize the body's own machinery - the T-cell - to target and destroy cancer
cells by using engineered, increased affinity TCRs as a means of strengthening
natural patient T-cell responses. Adaptimmune's lead program is a SPEAR T-cell
therapy targeting the NY-ESO cancer antigen. Its NY-ESO SPEAR T-cell therapy has
demonstrated signs of efficacy and tolerability in Phase 1/2 trials in solid
tumors and in hematologic cancer types, including synovial sarcoma and multiple
myeloma. Adaptimmune has a strategic collaboration and licensing agreement with
GlaxoSmithKline for the development and commercialization of the NY-ESO TCR
program. In addition, Adaptimmune has a number of proprietary programs. These
include SPEAR T-cell therapies targeting the MAGE-A10 and AFP cancer antigens,
which both have open INDs, and a further SPEAR T-cell therapy targeting the
MAGE-A4 cancer antigen that is in pre-clinical phase with IND acceptance
targeted for 2017. The company has identified over 30 intracellular target
peptides preferentially expressed in cancer cells and is currently progressing
12 through unpartnered research programs. Adaptimmune has over 250 employees and
is located in Oxfordshire, U.K. and Philadelphia, USA. For more
information: http://www.adaptimmune.com
Adaptimmune Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking
statements involve certain risks and uncertainties. Such risks and uncertainties
could cause our actual results to differ materially from those indicated by such
forward-looking statements, and include, without limitation: the success, cost
and timing of our product development activities and clinical trials and our
ability to successfully advance our TCR therapeutic candidates through the
regulatory and commercialization processes. For a further description of the
risks and uncertainties that could cause our actual results to differ materially
from those expressed in these forward-looking statements, as well as risks
relating to our business in general, we refer you to our Quarterly Report on
Form 10-Q filed with the Securities and Exchange Commission (SEC) on May
12, 2016 and our other SEC filings. The forward-looking statements contained in
this press release speak only as of the date the statements were made and we do
not undertake any obligation to update such forward-looking statements to
reflect subsequent events or circumstances.
*For research use or manufacturing of cell, gene, or tissue-based products.
Caution: Not intended for direct administration into humans or animals.
**Barrett et al (2014) Cytotherapy. Relation of clinical culture method to T-
cell memory status and efficacy in xenograft models of adoptive immunotherapy.
Adaptimmune Contacts
Will Roberts
Vice President, Investor Relations
T: (215) 825-9306
E: will.roberts(at)adaptimmune.com
Margaret Henry
Head of PR
T: +44 (0)1235 430036
Mobile: +44 (0)7710 304249
E: margaret.henry(at)adaptimmune.com
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Adaptimmune Therapeutics plc via GlobeNewswire
[HUG#2021957]
Unternehmensinformation / Kurzprofil:
Datum: 21.06.2016 - 13:30 Uhr
Sprache: Deutsch
News-ID 479107
Anzahl Zeichen: 7643
contact information:
Town:
Philadelphia
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 238 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Adaptimmune Announces Commercial Development and Supply Agreement for Thermo Fisher Scientific's Dynabeads(TM) CD3/CD28 Cell Therapy System"
steht unter der journalistisch-redaktionellen Verantwortung von
Adaptimmune Therapeutics plc (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
